TGF-β and IL-17 serum levels and specific immunotherapy

Giorgio Ciprandi; Mara De Amici; Simone Negrini; Gianluigi Marseglia; Maria Angela Tosca

doi:10.1016/j.intimp.2009.07.004

TGF-β and IL-17 serum levels and specific immunotherapy

Giorgio Ciprandi, Mara De Amici, Simone Negrini, Gianluigi Marseglia, Maria Angela Tosca

Research output: Contribution to journal › Article › peer-review

Abstract

Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels.

Original language	English
Pages (from-to)	1247-1249
Number of pages	3
Journal	International Immunopharmacology
Volume	9
Issue number	10
DOIs	https://doi.org/10.1016/j.intimp.2009.07.004
Publication status	Published - Sep 2009

Keywords

Allergic rhinitis
IL-17
Sublingual immunotherapy
TGF-β

ASJC Scopus subject areas

Immunology
Immunology and Allergy
Pharmacology

Access to Document

10.1016/j.intimp.2009.07.004

Fingerprint Dive into the research topics of 'TGF-β and IL-17 serum levels and specific immunotherapy'. Together they form a unique fingerprint.

Cite this

@article{d6b1c2513ac14e2fabab4441d67791ec,

title = "TGF-β and IL-17 serum levels and specific immunotherapy",

abstract = "Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels.",

keywords = "Allergic rhinitis, IL-17, Sublingual immunotherapy, TGF-β",

author = "Giorgio Ciprandi and {De Amici}, Mara and Simone Negrini and Gianluigi Marseglia and Tosca, {Maria Angela}",

year = "2009",

month = sep,

doi = "10.1016/j.intimp.2009.07.004",

language = "English",

volume = "9",

pages = "1247--1249",

journal = "International Immunopharmacology",

issn = "1567-5769",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - TGF-β and IL-17 serum levels and specific immunotherapy

AU - Ciprandi, Giorgio

AU - De Amici, Mara

AU - Negrini, Simone

AU - Marseglia, Gianluigi

AU - Tosca, Maria Angela

PY - 2009/9

Y1 - 2009/9

N2 - Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels.

AB - Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels.

KW - Allergic rhinitis

KW - IL-17

KW - Sublingual immunotherapy

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=68949170682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949170682&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2009.07.004

DO - 10.1016/j.intimp.2009.07.004

M3 - Article

C2 - 19622397

AN - SCOPUS:68949170682

VL - 9

SP - 1247

EP - 1249

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 10

ER -